These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

486 related items for PubMed ID: 28104258

  • 1. The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicentric cross-sectional survey in the western Balkan countries.
    Drulovic J, Cukic M, Grgic S, Dincic E, Raicevic R, Nadj C, Toncev G, Vojinovic S, Mesaros S, Kisic Tepavcevic D, Dujmovic I, Tadic D, Miletic-Drakulic S, Dackovic J, Kostic S, Erakovic J, Sakalas L, Savic D, Suknjaja V, Martinovic V, Maric G, Pekmezovic T.
    Mult Scler Relat Disord; 2017 Jan; 11():56-61. PubMed ID: 28104258
    [Abstract] [Full Text] [Related]

  • 2. Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β-1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.
    Hoffmann FA, Trenova A, Llaneza MA, Fischer J, Lus G, von Bredow D, Lara N, Lam E, Van Hoef M, Bakshi R.
    BMC Neurol; 2017 Aug 09; 17(1):156. PubMed ID: 28793876
    [Abstract] [Full Text] [Related]

  • 3. Supportive strategies to improve adherence to IFN β-1b in multiple sclerosis--results of the βPlus observational cohort study.
    Pozzilli C, Schweikert B, Ecari U, Oentrich W, BetaPlus Study group.
    J Neurol Sci; 2011 Aug 15; 307(1-2):120-6. PubMed ID: 21636099
    [Abstract] [Full Text] [Related]

  • 4. Adherence, satisfaction and functional health status among patients with multiple sclerosis using the BETACONNECT® autoinjector: a prospective observational cohort study.
    Kleiter I, Lang M, Jeske J, Norenberg C, Stollfuß B, Schürks M.
    BMC Neurol; 2017 Sep 06; 17(1):174. PubMed ID: 28877664
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cytokines and disability in interferon-β-1b treated and untreated women with multiple sclerosis.
    Trenova AG, Slavov GS, Manova MG, Kostadinova II.
    Arch Med Res; 2014 Aug 06; 45(6):495-500. PubMed ID: 25130430
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Evaluation of an electronic diary for improvement of adherence to interferon beta-1b in patients with multiple sclerosis: design and baseline results of an observational cohort study.
    Zettl UK, Bauer-Steinhusen U, Glaser T, Hechenbichler K, Limmroth V, Study Group.
    BMC Neurol; 2013 Sep 06; 13():117. PubMed ID: 24011220
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
    Verdun E, Isoardo G, Oggero A, Ferrero B, Ghezzi A, Montanari E, Zaffaroni M, Durelli L, Betaferon Safety Trial (BEST) Study Group.
    J Interferon Cytokine Res; 2002 Feb 06; 22(2):245-55. PubMed ID: 11911808
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Current status of interferon beta-1b in multiple sclerosis therapy].
    Hartung HP.
    Med Klin (Munich); 2001 Sep 15; 96 Suppl 1():11-6. PubMed ID: 11603110
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.